Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 11/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | ESR1 | P03372 | 1/20 | 0.57 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.57 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.57 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | GGT1 | P19440 | 1/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene SCHEMBL28225928 | 0.84 | PTGS2 (0.63) | PTGS2KDM4EHSD17B10ALDH1A1ESR1 | |
| SCHEMBL338196 | 0.84 | PTGS2 (0.68) | PTGS2KDM4EHSD17B10ALDH1A1ESR1 | |
| SCHEMBL29432883 | 0.84 | PTGS2 (0.68) | PTGS2KDM4EHSD17B10ALDH1A1ESR1 | |
| SCHEMBL3742376 | 0.83 | PTGS2 (0.57) | PTGS2KDM4EHSD17B10ALDH1A1ESR1 | |
| SCHEMBL11269983 | 0.82 | MAPK1 (0.61) | PTGS2KDM4EHSD17B10ALDH1A1ESR1 | |
| Iodide SCHEMBL30619798 | 0.81 | PTGS2 (0.65) | PTGS2KDM4EHSD17B10ALDH1A1ESR1 | |
| SCHEMBL8926560 | 0.79 | KDM4E (0.59) | KDM4EHSD17B10ALDH1A1HPGDTSHR | |
| SCHEMBL8926773 | 0.78 | KMT2A (0.43) | PTGS2KDM4EHSD17B10ALDH1A1ESR1 | |
| SCHEMBL6623023 | 0.78 | ELANE (0.46) | PTGS2KDM4EHSD17B10ALDH1A1ESR1 | |
| SCHEMBL8927620 | 0.78 | NCEH1 (0.51) | ALDH1A1TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 347 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4178959-A1 | NITROGEN HETEROCYCLIC CYTOKININ DERIVATIVES, COMPOSITIONS CONTAINING THESE DERIVATIVES AND USE THEREOF | Univerzita Palackého v Olomouci (CZ) | 2023-05-17 | — | — | EP | claimed |
| US-11643413-B2 | 9-(2-oxacycloalkyl)-9H-purine-2,6-diamine derivatives and their use for the treatment of skin disorders | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2023-05-09 | — | — | US | claimed |
| CN-114716386-A | Novel exosome inhibitor and preparation method thereof | 北京和理咨询有限公司 | 2022-07-08 | — | — | CN | claimed |
| EP-3615535-B1 | 9-(2-OXACYCLOALKYL)-9H-PURINE-2,6-DIAMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SKIN DISORDERS | UNIV PALACKEHO (CZ) | 2022-06-15 | — | — | EP | claimed |
| WO-2022012702-A1 | NITROGEN HETEROCYCLIC CYTOKININ DERIVATIVES, COMPOSITIONS CONTAINING THESE DERIVATIVES AND USE THEREOF | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2022-01-20 | — | — | WO | claimed |
| US-20200157105-A1 | 9-(2-OXACYCLOALKYL)-9H-PURINE-2,6-DIAMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SKIN DISORDERS | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2020-05-21 | — | — | US | claimed |
| EP-3615535-A1 | 9-(2-OXACYCLOALKYL)-9H-PURINE-2,6-DIAMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SKIN DISORDERS | Univerzita Palackého v Olomouci (CZ) | 2020-03-04 | — | — | EP | claimed |
| WO-2018196893-A1 | 9-(2-OXACYCLOALKYL)-9H-PURINE-2,6-DIAMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SKIN DISORDERS | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2018-11-01 | — | — | WO | claimed |
| US-9809822-B2 | Triptolide derivatives and preparation method and use thereof | HONG KONG BAPTIST UNIVERSITY (HK) | 2017-11-07 | — | — | US | claimed |
| US-20160362691-A1 | TRIPTOLIDE DERIVATIVES AND PREPARATION METHOD AND USE THEREOF | HONG KONG BAPTIST UNIVERSITY (HK) | 2016-12-15 | — | — | US | claimed |
| WO-1994022840-A1 | SUBSTITUTED CAPROLACTAMS AND DERIVATIVES THEREOF USEFUL FOR TREATMENT OF HIV DISEASE | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-10-13 | — | — | WO | claimed |
| WO-1994019329-A1 | SUBSTITUTED CYCLIC CARBONYLS AND DERIVATIVES THEREOF USEFUL AS RETROVIRAL PROTEASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-09-01 | — | — | WO | claimed |
| EP-0594588-A1 | CYCLOALKYL-SUBSTITUTED GLUTARAMIDE ANTIHYPERTENSIVE AGENTS | Pfizer Limited (GB) | 1994-05-04 | — | — | EP | claimed |
| US-5210315-A | Oxidizing olefins using a ruthenium catalyst | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1993-05-11 | — | — | US | claimed |
| EP-0358398-B1 | CYCLOALKYL-SUBSTITUTED GLUTARAMIDE ANTIHYPERTENSIVE AGENTS | Pfizer Limited (GB) | 1993-03-10 | — | — | EP | claimed |
| WO-1991013054-A1 | CYCLOALKYL-SUBSTITUTED GLUTARAMIDE ANTIHYPERTENSIVE AGENTS | PFIZER LIMITED (GB) | 1991-09-05 | — | — | WO | claimed |
| EP-0358398-A1 | Cycloalkyl-substituted glutaramide antihypertensive agents | Pfizer Limited (GB) | 1990-03-14 | — | — | EP | claimed |
| EP-0143399-B1 | CYSTEINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSTIONS WHICH CONTAIN THEM | MAGIS FARMACEUTICI S.P.A. (IT) | 1988-07-06 | — | — | EP | claimed |
| EP-0257344-A1 | Medicaments containing dipyridamol or mopidamol and O-acetylsalicylic acid, or its physiologically compatible salts, process for their manufacture and their use in combating the formation of thrombus | Dr. Karl Thomae GmbH (DE) | 1988-03-02 | — | — | EP | claimed |
| US-4687844-A | Process for the direct preparation of N,N-disubstituted derivatives for 4,13-diaza-18-crown-6 | UNIVERSITY OF MARYLAND (US) | 1987-08-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157105-A1 | 9-(2-OXACYCLOALKYL)-9H-PURINE-2,6-DIAMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SKIN DISORDERS | ADORA2A, UNG, P2RY6 | PTGS2 472/4885KDM4E 1335/4885HSD17B10 3638/4885 |
| US-11643413-B2 | 9-(2-oxacycloalkyl)-9H-purine-2,6-diamine derivatives and their use for the treatment of skin disorders | ADORA2A, UNG, P2RY6 | PTGS2 472/4885KDM4E 1335/4885HSD17B10 3638/4885 |
| US-20160362691-A1 | TRIPTOLIDE DERIVATIVES AND PREPARATION METHOD AND USE THEREOF | TPD52L2, TRDMT1, MCTS1 | PTGS2 3308/4885KDM4E 2236/4885HSD17B10 3738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.